59
Participants
Start Date
November 1, 2022
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2028
Obinutuzumab
"Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions);~Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression"
lenalidomide
"Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6;~Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression"
RECRUITING
Institute of Hematology & Blood Diseases Hospital, Tianjin
Institute of Hematology & Blood Diseases Hospital, China
OTHER